Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bid squeezing Ask !!! Will go higher
Good buying pressure !!!
RECOVERY day with Potential News !!!!!!
TODAY 1-18-18
Positive Buying Pressure Spotted in Shares of Biocorrx Inc (BICX)
January 18, 2018
Biocorrx Inc (BICX) is seeing positive money flow as the Chalkin (CMF) indicator is holding above the zero line. The Chaikin Money Flow Indicator is an oscillator developed by Marc Chaikin. An oscillator is an indicator that is used as a counter trend showing when the market is overbought or oversold. The CMF is based largely on the Accumulation Distribution Line; it compares the close value with the high and the low for that same day.
A buy signal occurs when the CMF value crosses from below the 0 line to above the 0 line. A sell signal occurs when the CMF value crosses from above the 0 line to below the 0 line.
Taking a look at some additional technical indicators, we see that currently Biocorrx Inc (BICX)’s Williams Percent Range or 14 day Williams %R is resting at -23.60. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to help define a specific trend.
Biocorrx Inc (BICX) presently has a 14-day Commodity Channel Index (CCI) of 135.60. Typically, the CCI oscillates above and below a zero line. Normal oscillations tend to stay in the range of -100 to +100. A CCI reading of +100 may represent overbought conditions, while readings near -100 may indicate oversold territory. Although the CCI indicator was developed for commodities, it has become a popular tool for equity evaluation as well. Checking on another technical indicator, the 14-day RSI is currently sitting at 68.40, the 7-day rests at 66.65, and the 3-day is presently at 58.85 for Biocorrx Inc (BICX).
Investors have the ability to approach the stock market from various angles. This may include using technical analysis, fundamental analysis, or a combination or the two. Investors watching the technical levels may be trying to chart patterns and discover trends in stock price movement. Investors tracking the fundamentals may be looking closely at many different factors. They may be focused on industry performance, earnings estimates, dividend payouts, and other factors. They might also be studying how the company is run, and trying to figure out the true value of the firm. Keeping track of all the data may seem overwhelming, but it may help give a needed boost to the portfolio.
The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stock’s price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.
Moving average indicators are commonly tracked by technical stock analysts. Many traders will use a combination of moving averages with multiple time periods to help spot stock trend direction. One of the more popular combinations is to use the 50-day and 200-day moving averages. Investors may use the 200-day MA to help smooth out the data a get a clearer long-term picture. They may look to the 50-day or 20-day to get a better grasp of what is going on with the stock in the near-term. Presently, the 200-day moving average is at 0.12, and the 50-day is 0.11. The 14-day ADX for Biocorrx Inc (BICX) is standing at 43.47. Many chart analysts believe that an ADX reading over 25 would suggest a strong trend. A reading under 20 would suggest no trend, and a reading from 20-25 would suggest that there is no clear trend signal.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Will see 0.30+ in no time ! Get ready
HYG! Fly
0.24 up !!!!
0.235 on the ask .... we are going up !! 0.30 very soooooooon ... go BICX
Making money already ? 0.23 got hit
Bid UP Squeezing the ASK !!! 0.2225
4 business days till the Big FDA meeting ... Gooo BICX !!!
Hahahah ! You are just funny .. if you are that desperate for BICX shares just say it ... I'll give you some of mine :)
BIOCORRX RANKED #2 IN THE GLOBAL ALCOHOL ADDICTION THERAPEUTIC MARKET !!!
01-17-2018 07:48 AM CET - Business, Economy, Finances, Banking & Insurance
Alcohol Addiction Therapeutics Global Market Key Trends, Size, Growth, Shares And Forecast Research Report 2017
Press release from: Researchmoz.us
Alcohol Addiction Therapeutics Market
Alcohol Addiction Therapeutics Market
Researchmoz added Most up-to-date research on "Global Alcohol Addiction Therapeutics Market Research Report 2017" to its huge collection of research reports.
In this report, the global Alcohol Addiction Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Alcohol Addiction Therapeutics in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India
To Get Sample Copy of Report visit @ www.researchmoz.us/enquiry.php?type=S&repid=1444782
Global Alcohol Addiction Therapeutics market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
AstraZeneca Plc
BioCorRx Inc
Bionex Pharmaceuticals LLC
Cerecor Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Curemark LLC
Eli Lilly and Company
Ethypharm SA
H. Lundbeck A/S
Heptares Therapeutics Ltd
Indivior Plc
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co Ltd
Lohocla Research Corp
Montisera Ltd
Omeros Corp
Opiant Pharmaceuticals Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
CM-1212
CTDP-002
A-705253
ABT-436
ADX-71441
Others
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Hospital
Clinic
Others
will slowly move up towards the 0.30 ... good day to accumulate more shares if needed ...
Bid Up 0.219
So he wants back in ? Looooool
100% Agree
No Sir , you are 100% Wrong .
6 business days till the FDA meeting !!! 6 more opportunities to add more shares ... Go BICX !!!!!!
Pip PM your email address
20 minutes buuuuuuuuuuuuuuuuuuuuuuuuy
between 0.30 and 0.40 by mid next week .
0.2325 on the ASK !
0.25+ before End Of Day !!!
0.215 :) Anyone wants in ?
Another 1 hr 30 min till end of trading day ..... next week different levels .... !!!
7 more business days !!!! BOOOOOM
0.21 on the ask !!
My buy order is set at 0.20 .... will wait for it :)
The good thing about Today's PR is that all the other stocks PPS mentioned in it ranges between $0.71 and $1.21 ( PLX $0.71, PTN $0.87, RGLS $1.21 , SBOT $0.93 ) ....
while BICX is at $0.18 ... means there is a HUGE upward potential here ... GO BICX !!!!
BICX getting ready to explode !! may be today !!
Biotech and Pain Management Therapeutics Segments Projected to Grow
9:00 AM ET 1/12/18 | PR Newswire
BICX
0.18 0.00%
PLX
0.71 0.00%
PTN
0.87 0.00%
RGLS
1.21 0.00%
SBOT
0.93 0.00%
FinancialBuzz.com News Commentary
NEW YORK, January 12, 2018 /PRNewswire/ --
According to EP Vantage, the editorial arm of Evaluate Ltd., in 2017 the FDA has given green light to 43 novel drugs, which are forecast to be generating a combined $32bn in US sales in five-years' time. The report indicates that the upward momentum seen in the pharma and biotech sectors during 2017 is expected to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong. Amy Brown, report author, explained, "Venture capital funds are very well stocked going into 2018, and both public and private investors look set to remain supportive of innovative, early-stage drug developers... However, there is evidence that expectations have got ahead of themselves in certain areas - particularly in immuno-oncology. To keep investors on side next year the industry needs to deliver some big pipeline wins, and important new drug launches need to perform." BioCorRx Inc. (OTC: BICX), Palatin Technologies, Inc. (NYSE: PTN), Stellar Biotechnologies, Inc. (NASDAQ: SBOT), Protalix BioTherapeutics, Inc. (NYSE: PLX), Regulus Therapeutics Inc. (NASDAQ: RGLS)
Opioids are the most widely prescribed medications or the treatment of chronic pain conditions, which is a major sector of the pharma and biotech industries. According to business intelligence provider GBI Research, the U.S. market for opioids will grow to $17.7 billion by 2021, at a compound annual growth rate of 7 percent. The report indicates that the U.S. consumes 80 percent of the world's legal and illegal opioids, which are highly addictive and are the country's most abused prescription drug. Deekshita Allavarapu, Analyst for GBI Research, explains: "The FDA has raised concerns over the high use, and the potential for misuse, of opioids. This could lead to the enforcement of regulatory checks that affect the opioid treatment market and its potential growth."
BioCorRx Inc. (OTCQB: BICX) on January 5(th) the company announced breaking news that, "it has retained regulatory drug experts Priya Jambhekar and Bruce Firestone, PhD, to assist with the drug development and regulatory process for BioCorRx's product pipeline. Ms. Jambhekar and Dr. Firestone are additions to the Company's current team, which is preparing for its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) scheduled on January 24, 2018. As previously announced, the Company is seeking FDA approval for BICX102, a naltrexone implant for the treatment of opioid and alcohol use disorders.
Ms. Jambhekar is a drug development entrepreneur with over 25 years of executive experience in worldwide regulatory, quality, clinical and pharmacovigilance operations, as well as early and late stage development product registration and commercial support. She has held positions including Global Senior Vice President of Regulatory & Quality Operations at Paramount BioSciences, Global Vice President at Ethicon, a Johnson & Johnson company, and Worldwide Vice President of Regulatory and Government Relations at Alkermes. Other senior positions include Baxter ACC, as Regulatory Head of Compliance, and Bristol-Myers Squibb, as Manager of Regulatory, Safety, Compliance. She is also certified by the Regulatory Affairs Professional Society and the New Jersey Pharmaceutical Quality Control and Assurance Society.
Dr. Firestone has over three decades of pharmaceutical research & development experience with on-time delivery of over 15 product approvals as new chemical entities and line extensions. Dr. Firestone is an accomplished author with over 40 publications, abstracts and patents. He also has extensive chemistry, manufacturing and controls (CMC) expertise with: small molecules, drug and drug-device combinations, sustained-release products, semisolids, topical and intravitreal routes of administration. He has held senior positions at Allergan and is an expert in pharmaceutical product development, manufacturing process development and scale-up, technology transfer, process validation, risk management, technology assessment, due diligence, CMC documentation, and CMC strategy."
Brady Granier, President, CEO and Director, stated, "Priya and Bruce are valuable additions to the BioCorRx team and we are honored to have them on board. They both bring extensive regulatory and manufacturing experience in drug development and have proven track records bringing drugs to market. We look forward to their contributions as we accelerate our efforts to obtain FDA approval for our naltrexone product that we feel will help many families suffering from the current opioid epidemic and massive alcohol dependence problem."
Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Recently, the company announced that the U.S. Food and Drug Administration (FDA) has notified Palatin that it may proceed with its clinical investigation of subcutaneous injection PL-8177 as a potential treatment for patients with ulcerative colitis. The notice to proceed was received following Palatin's submission of an investigational new drug (IND) application for this program. Palatin expects to commence a Phase 1 single and multiple ascending dose study in the current quarter. PL-8177, a selective melanocortin receptor 1 (MC1r) agonist peptide, is Palatin's lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases. Agents that modulate the MC1r system may have therapeutic potential in a variety of inflammatory disease indications.
Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function. On December 1, 2017, the company reported financial results for the fiscal year ended September 30, 2017 and provided an update on its business. During fiscal year 2017, the company advanced a number of strategic initiatives to optimize its manufacturing operations and to secure additional locations for the biologic source of KLH. Stellar currently has multiple customers with KLH-based drug candidates in Phase 2 studies. While the outcomes of these clinical studies cannot be predicted, the company is preparing for the possible impact that favorable clinical results could have on the KLH market and the company's supply capabilities.
Protalix BioTherapeutics, Inc. (NYSE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. On January 2, 2018, the company announced interim data from the first 14 patients that completed, to date, the Company's phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis. The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. On December 19, 2017, the company announced that it has initiated the first-in-human Phase I study of RGLS4326 and completed dosing of the first cohort of healthy volunteers. RGLS4326 is in development for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. RGLS4326 is being studied in a Phase I randomized, double-blind, placebo-controlled, single ascending dose study designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS4326 administered subcutaneously in healthy volunteers.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
(MORE TO FOLLOW) Dow Jones Newswires
January 12, 2018 09:00 ET (14:00 GMT)
Biotech and Pain Management Therapeutics Segments -2-
VERY GOOD ARTICLE 1/11/18
Biotech Companies May Be Primed For 2018; New Regulations, Fast Approval
By Komfie ManaloStock Markets6 hours ago (Jan 11, 2018 07:35AM ET)
Komfie Manalo
Komfie Manalo Articles (6)
Biotech firms had a good year in 2017. The NASDAQ Biotechnology Index reported a 20% jump as of early December even after a 10% correction since October.
This year appears to hold more promise for the biotech sector with diminished risk of stringent regulations, particularly with the drug price rule that has significantly subsided. In addition, the Trump administration issued a policy initiative in July to accelerate the approval process for new drugs.
With the US Food and Drug Administration (FDA) now at the forefront of the administration’s price-cutting initiative, the agency has been tasked with speeding up the drug approval process. These moves may be considered highly favorable to the biotech sector and are expected to provide further activity.
One of the companies which may potentially benefit from these changes in policy, combined with the current U.S. opioid crisis, is Biocorrx Inc (OTC:BICX), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. They recently announced that they have submitted their pre-Investigational New Drug (pre-IND) package to the FDA for the company's naltrexone implant, BICX102. BICX102 is the company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The submitted pre-IND package provides the FDA with current information on BICX102, as well as the proposed development plan. The purpose of the meeting is to review the development plan and to seek the agency’s guidance on further development and commercialization of BICX102.
This pre-IND submission follows BioCorRx's recent announcement that the FDA has granted BioCorRx a Type-B pre-IND meeting that is scheduled for January 24, 2018. The National Institute on Drug Abuse (NIDA) has agreed to attend the pre-IND meeting with the FDA for BICX102. NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA) have also received the documents which BioCorRx submitted to the FDA.
Brady Granier, CEO, president, and director of BioCorRx, commented, “We are pleased that BioCorRx will be starting out the New Year with a meeting with the FDA. The submission of the pre-IND package is a major step that BioCorRx has completed in its efforts to bring BICX102 to market. We thank all of our advisors and consultants for their tireless efforts in putting together a package that we feel will lead to a very productive meeting. We are pursuing the 505(b)(2) regulatory pathway, which we believe will be a more rapid and cost-effective route to approval. We are pleased that both NIDA and NIAAA are involved in this process and we look forward to the meeting with the FDA.”
Top Biotech Performers of 2017
Investors who are on the lookout for opportunities in the biotech sector need to take a quick peek into this year’s top performers. Here are the top three performing biotech sectors with market capitalization between $50 and $500 million that are traded on the NASDAQ and the TSX.
1. XOMA Corp (NASDAQ:XOMA)
This Berkeley, California-based company saw a 656.4% increase in its share prices in 2017. Xoma boasts of seeking “transactions where it could exchange cash or equity today for future milestones and royalties.”
Chief Executive Officer Jim Neal stated in the company’s third-quarter report that Xoma “is very well positioned to deliver sustained growth in the years ahead and create long-term value for shareholders" because of the more than two dozen partner-funded programs that have the potential to generate substantial additional milestone and royalty payments.
2. AVEO Pharmaceuticals Inc (NASDAQ:AVEO)
Based in Cambridge, Massachusetts, and founded by Ronald DePinho in 2018, AVEO is reporting a 443.52% rise and share price value this year.
The company is also expecting U.S. approval for its FOTIVDA (tivozanib) in the first quarter of 2018 after the completion of a study in subjects with refractory advanced renal cell carcinoma. FOTIVDA (tivozanib) is AVEO’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway.
AVEO is confident it can fully explore its opportunities in the oncology segment of the biotech industry.
3. Viking Therapeutics Inc (NASDAQ:VKTX)
Headquartered in California, Viking Therapeutics stocks jumped 245.38 in 2017. Viking is devoted to developing therapies for the metabolic and endocrine disorder.
Viking Chief Executive Officer Brian Lian said the company is scheduled to announce the results of Phase 2 trial of the company’s novel SARM program VK5211 in patients recovering from hip fracture by year-end.
VK5211, Viking's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate. The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled, parallel group, international study designed to evaluate the efficacy, safety, and tolerability of VK5211 in patients recovering from hip fracture surgery.
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I am receiving compensation from BioCorRx for the article.
latest news !!!
https://www.biocorrx.com/news-media/press-releases
Today's PPS range 0.20 - 0.25 !!!!!